scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

SCPH Stock  USD 3.45  0.16  4.86%   
Under 55% of Scpharmaceuticals' investor base is interested to short. The analysis of overall sentiment of trading Scpharmaceuticals stock suggests that many investors are impartial at this time. Scpharmaceuticals' investing sentiment shows overall attitude of investors towards Scpharmaceuticals.
  
Generated 3Q 2024 net FUROSCIX revenue of 10.0 million, up 164 percent from Q3 2023 Received approval of label expansion to include New York Heart Association Class IV Patients Announced positive pharmacokineticpharmacodynamic data on Autoinjector program Completed 125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, Novembe

Read at finance.yahoo.com
Yahoo News
  

Scpharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Scpharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Scpharmaceuticals Fundamental Analysis

We analyze Scpharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scpharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scpharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Gross Profit

Gross Profit Comparative Analysis

Scpharmaceuticals is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Scpharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scpharmaceuticals stock to make a market-neutral strategy. Peer analysis of Scpharmaceuticals could also be used in its relative valuation, which is a method of valuing Scpharmaceuticals by comparing valuation metrics with similar companies.

Peers

Scpharmaceuticals Related Equities

MNPRMonopar Therapeutics   9.54   
0%
100.0%
MCRBSeres Therapeutics   6.17   
0%
64.0%
CNTACentessa Pharmaceuticals   2.23   
0%
23.0%
MISTMilestone Pharmaceuticals   1.00   
0%
10.0%
DMACDiaMedica Therapeutics   0.68   
7.0%
0%
KTTAPasithea Therapeutics   1.59   
16.0%
0%
IOVAIovance Biotherapeutics   1.94   
20.0%
0%
LYRALyra Therapeutics   5.26   
55.0%
0%
ONCYOncolytics Biotech   7.59   
79.0%
0%

Complementary Tools for Scpharmaceuticals Stock analysis

When running Scpharmaceuticals' price analysis, check to measure Scpharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scpharmaceuticals is operating at the current time. Most of Scpharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Scpharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scpharmaceuticals' price. Additionally, you may evaluate how the addition of Scpharmaceuticals to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets